Spain’s new patent law came into force on April 1, and it contains a few measures which will affect pharmaceutical companies, says Dámaso Gallardo of Clarke Modet & Co.
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.
Intellectual property in the life sciences arena can be an attractive investment target, but a long process of evaluation must take place first, cautions Dimitar Georgiev, founder and CEO of Paralax Life Sciences.
The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.
The UK’s vote to leave the EU may allow Britain to replace the SPC regulation—an often-criticised piece of law—and take a fresh approach to the system governing these rights, say Paul England and Matthew Royle of Taylor Wessing.
The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker.
The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins.
Global companies are watching a pending life sciences patent case at the US Supreme Court because of its potential impact both within and outside US borders, as Sandra Kuzmich and Russell Garman of Frommer Lawrence & Haug explain.
In September 2016, the Francis Crick Institute opened the doors to its multimillion-pound new home in London. With a wide range of research being undertaken, LSIPR examines the role of IP and the associated challenges for the organisation.
On December 7, LSIPR will be hosting the Life Sciences Patents Network Europe 2016 at the Bloomsbury Hotel in London. Here we preview the main talking points.